http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
North Highland Named a Major Player in IDC MarketScape: Worldwide Employee Experience Consulting Services 2024 Vendor Assessment
-
L3Harris Awards CPI Aerostructures, Inc. Contract for Next Generation Jammer Low-Band Program
-
Dalrada Financial Corporation Announces the Addition of Roger Campos to Its Board of Directors
-
The Identity Theft Resource Center Predicts a Decrease in Victim Support and Increase in ID Crimes in its 2025 Predictions
-
Jacobs (J) Awarded Contract for Metro Vancouver Critical Water Program
-
Arrowhead Pharmaceuticals Presents Interim Clinical Data on ARO-CFB for the Treatment of Complement Mediated Diseases
-
Condado Tacos is spicing up their growth plan with a new secret ingredient: PAR Technology’s Data Central
-
Celcuity (CELC) Presents Overall Survival Data from Phase 1b Study Evaluating Gedatolisib in Combination with Palbociclib and Endocrine Therapy
-
Celcuity Presents Overall Survival Data from Phase 1b Study Evaluating Gedatolisib in Combination with Palbociclib and Endocrine Therapy at the 2024 San Antonio Breast Cancer Symposium
-
PureTech Founded Entity Seaport Therapeutics Presents Additional Data from Phase 1 Study of SPT-300 at ACNP Annual Meeting 2024
-
PolyPid Ltd. (PYPD) Announces Research and Development Collaboration with ImmunoGenesis Leveraging PLEX Technology to Enhance Cancer Immunotherapy
-
PolyPid Announces Research and Development Collaboration with ImmunoGenesis Leveraging PLEX Technology to Enhance Cancer Immunotherapy
-
Railtown AI to Present at the AInBC Demo Night
-
GXO reaches new heights with extension for Guess
-
GFG Announces Proceeds of C$3.7 Million from Warrant Exercise Accelerates Exploration Programs in Timmins
-
Interfacing recognized as a DTO Leader in Gartner®'s Latest Report
-
Relay Therapeutics Announces Updated Interim Data for RLY-2608 + Fulvestrant Demonstrating Continued Maturation of Clinically Meaningful Progression Free Survival
-
Tate & Lyle and BioHarvest Announce Partnership to Drive the Future of Ingredients Through Botanical Synthesis Technology
-
Mega Matrix Announced that Action-Packed Revenge Drama "License to Wed and Kill" Premiered on FlexTV on December 10
-
Bitget Announces Launch of BGBTC, Wrapped Bitcoin Token Backed by 1:1 BTC Reserves
-
Dizal Announces Positive Pooled Data of Sunvozertinib in EGFR Tyrosine Kinase Inhibitor-Resistant Non-Small Cell Lung Cancer Published in Lung Cancer
-
Engage3 Welcomes RetailWire CEO Dominick Miserandino to Technology Board to Drive Retail, Brand and E-Commerce Innovation
-
BluSky Carbon Signs LOI for US$192 Million AR2 Biochar Project
-
Discover the GHOAD (Ghoad) Listing on XT
-
SPS North America Receives Top Honors in HR Strategy for its Elevate Training Program
-
BearingPoint client success story: JobRad Leasing ensures sustainable business growth through a successful financing transaction
-
Discover the EBC (Epic Ballad Coin) Listing on XT
-
SES Equips Peruvian Air Force with High-throughput Connectivity via SES-14 Satellite
-
Eltawfiq Creations Elevates Clients' Brand Presence with Captivating Visual Narratives and Digital Solutions
-
Evotec SE announces first projects for LAB eN(2) drug discovery accelerator with Novo Nordisk
-
Gold Mountain Announces $1.5 Million Flow-Through Private Placement
-
TEAMSTERS APPLAUD KROGER-ALBERTSONS INJUNCTION
-
American Lithium Announces Intention to Voluntarily Delist Its Common Shares From Nasdaq Capital Market
-
Awakn Announces Promising Results from Aminoindane New Chemical Entity Pre-Clinical Program
-
ALC’s Flexible Financing Approach For Rural Hospital Gets Federal Approval
-
Mawson Infrastructure Group (MIGI) Announces Monthly Operational Update for November 2024
-
Cellectar Biosciences (CLRB) Provides Strategic Update on Clinical Development, Pipeline Programs and Corporate Restructuring
-
Mawson Infrastructure Group Inc. Announces Monthly Operational Update for November 2024
-
Cellectar Biosciences Provides Strategic Update on Clinical Development, Pipeline Programs and Corporate Restructuring
-
Victory Capital Reports November 2024 Total Client Assets
-
Cellectis announces the drawdown of the third tranche of €5 million under the credit facility agreement entered with the European Investment Bank (EIB)
-
Q32 Bio (QTTB) SIGNAL-AD trial did not achieve its primary endpoint, SIGNAL-AA demonstrated encouraging clinical activity
-
Morningstar (MORN) Appoints Michael Holt as Chief Financial Officer
-
Loop Media Reports Full Year 2024 and Fiscal Fourth Quarter Financial Results
-
Morningstar Appoints Michael Holt as Chief Financial Officer
-
Phillips Edison & Company Reveals Retail Trends in Commercial Real Estate for 2025
-
Repare Therapeutics to Host Webcast to Report Data from the Lunresertib and Camonsertib Combination Phase 1 MYTHIC Clinical Trial
-
Q32 Bio Provides Bempikibart Program Update, Including Next Steps for Advancing Alopecia Areata Development Program
-
Phillips Edison & Company Reveals Retail Trends in Commercial Real Estate for 2025
-
Hologic (HOLX) Statement on USPSTF Draft Cervical Cancer Screening Guidelines


